ArticleCureus2026
TRIM59 (Tripartite Motif-Containing 59) Expression in Pan-Cancer and Its Diagnostic and Prognostic Implications in Breast Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, and Stomach Adenocarcinoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cancers remain a significant global health challenge; identification of cutting-edge diagnostic and prognostic markers plus innovative therapeutic targets is crucial. Tripartite motif molecule 59 (TRIM59) is a potential oncogene. However, its specific role in cancers is lacking. We aimed to investigate the expression of TRIM59 in pan-cancer as well as its implications for tumorigenesis, clinicopathological factors, and immune cell infiltration. Moreover, we aimed to investigate the protein-protein interaction and evaluate its potential as a diagnostic and prognostic biomarker in pan-cancer using bioinformatic analysis. Methods We analyzed TRIM59 across different cancer types using public datasets and bioinformatics tools. To study gene expression patterns, we used gene expression profiling interactive analysis (GEPIA), University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN), tumor immune estimation resource (TIMER), and University of California, Santa Cruz (UCSC) Xena, and validated our findings using additional datasets from the Gene Expression Omnibus (GEO) datasets. We assessed diagnostic performance with receiver operating characteristic (ROC) curve analysis. We also used Kaplan-Meier plotter (K-M plotter), GEPIA, UALCAN, and TIMER to explore how TRIM59 expression relates to patient prognosis and immune cell infiltration. Genetic changes were examined with cBioPortal, while the search tool for recurring instances of neighboring genes (STRING) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis helped us study protein-protein interaction networks and pathway enrichment. For statistical analysis, we used the Limma (Linear Models for Microarray Analysis) program and standard tests. Results TRIM59 was significantly upregulated in 22 cancers, with the highest level of expression in breast cancer (BRCA), esophageal cancer (ESCA), lung squamous cell carcinoma (LUSC), and stomach adenocarcinoma (STAD). High TRIM59 expression is significantly associated with a worse prognosis in kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and lung adenocarcinoma (LUAD), and it was also associated with various clinicopathological factors in BRCA, ESCA, LUSC, STAD, and immune markers across all these cancers. High TRIM59 expression is associated with infiltration of different immune cells in BRCA, ESCA, LUSC, STAD, LIHC, KIRP, and LUAD. Also, TRIM59 is associated with various genetic alterations across different types of tumors, and it interacts with several proteins. Conclusion In this study, we found that TRIM59 contributes to the carcinogenesis and increased malignant behavior of BRCA, ESCA, STAD, LUSC, LUAD, and KIRP. We also found that TRIM59 is a potential diagnostic biomarker for BRCA, ESCA, LUSC and STAD and a prognostic biomarker for KIRP, LIHC, and LUAD. Moreover, it correlates with immune infiltration and may be relevant to immunotherapy in these cancers. Furthermore, its correlation with tumor protein 53 (TP53), alpha/beta hydrolase domain containing 5 (ABHD5), and evolutionarily conserved signaling intermediate in toll pathway (ECSIT) may be used as a potential area of therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.